• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cara Therapeutics Inc.

    4/22/24 4:08:10 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CARA alert in real time by email
    DEFA14A 1 tm242755d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

     

    Filed by the Registrant x
       
    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under § 240.14a-12

     

    CARA THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    xNo fee required.

     

    ¨Fee paid previously with preliminary materials.

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

       

     

    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V48429-P09692 CARA THERAPEUTICS, INC. 400 ATLANTIC STREET SUITE 500 STAMFORD, CT 06901 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the Notice and Proxy Statement and Annual Report, and to obtain directions to attend the virtual meeting, go to: www.ProxyVote.com. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. CARA THERAPEUTICS, INC. 2024 Annual Meeting Vote in advance by June 3, 2024 11:59 PM ET You invested in CARA THERAPEUTICS, INC. and it’s time to vote! Stockholders of record as of the close of business on April 8, 2024 have the right to vote on proposals being presented at the 2024 Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 4, 2024. Vote Virtually at the Meeting* June 4, 2024 12:00 PM EDT Virtually at: www.virtualshareholdermeeting.com/CARA2024 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote View the Annual Report and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 21, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V48430-P09692 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of the Board of Directors’ two nominees for director to serve until the Company’s 2027 Annual Meeting and until their successors are duly elected and qualified. Nominees: For 01) Susan Shiff, Ph.D. 02) Helen M. Boudreau 2. Approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. For 3. Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. For 4. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares. For 5. Approval of a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of the Board of Directors, a reverse stock split of the Company’s common stock at a reverse stock split ratio ranging from one-for-four (1:4) to one-for-twelve (1:12), inclusive, and a corresponding proportionate reduction in the total number of authorized shares of the Company’s common stock, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board of Directors prior to the date of the 2025 Annual Meeting of Stockholders. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment, continuation, or postponement thereof. You may attend and vote during the Annual Meeting via the Internet. Have the information that is printed in the box marked with the arrow on your proxy card or Notice of Internet Availability of Proxy Materials available and follow the instructions.

    Get the next $CARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARA

    DatePrice TargetRatingAnalyst
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    6/13/2024Buy → Hold
    Needham
    6/13/2024Buy → Neutral
    H.C. Wainwright
    3/8/2023$13.00 → $6.00Neutral → Underperform
    BofA Securities
    3/8/2022$17.00 → $20.00Neutral → Overweight
    JP Morgan
    11/1/2021$33.00Buy
    Canaccord Genuity
    8/24/2021$33.00 → $35.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CARA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

    STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that its Board of Directors (the "Board") has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara's common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on Wednesday, April 16, 2025 under the new name "Tvardi Therapeutics, Inc." and under the new symbol "TVRD" following the anticipated closing of the merger (the "Merger") with Tvard Therapeutics, Inc. ("Tvardi"), with a new CUSIP number 140755 307. The reverse stock split was approved by Cara's stockholders at Cara's special

    4/14/25 11:50:29 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

    STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Tuesday, December 31, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "CARA" with the new CUSIP number, 1

    12/27/24 7:00:00 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

    Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

    12/18/24 7:00:00 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    SEC Filings

    View All

    Cara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure, Other Events

    8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    4/15/25 4:06:29 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

    4/11/25 4:16:03 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

    4/1/25 4:30:32 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    4/21/25 5:15:20 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    4/21/25 5:15:32 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    4/21/25 5:15:30 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cara Therapeutics downgraded by Stifel with a new price target

    Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously

    6/13/24 7:05:24 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously

    6/13/24 7:05:04 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics downgraded by Needham

    Needham downgraded Cara Therapeutics from Buy to Hold

    6/13/24 7:04:33 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    Financials

    Live finance-specific insights

    View All

    Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

    Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

    12/18/24 7:00:00 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

    –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio

    3/4/24 4:01:00 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

    STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co

    2/12/24 4:01:00 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    Leadership Updates

    Live Leadership Updates

    View All

    Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

    STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards. "We are pleased to welcome Helen to the Cara board," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "We look forward to leveraging her

    8/3/23 7:00:00 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KemPharm Announces Appointment of Christopher Posner as New Independent Director

    24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.

    11/29/22 7:30:00 AM ET
    $CARA
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

    STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors. Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. "We are very pleased to welcome Lisa to our board of directors," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "Her extensive clinical development and pharmacology expertise will be of great value as we continue executing o

    11/3/22 7:00:00 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Cara Therapeutics Inc.

    SC 13D - Cara Therapeutics, Inc. (0001346830) (Subject)

    10/30/24 4:21:50 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

    SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

    2/13/24 6:50:36 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

    SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

    2/13/24 5:01:02 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care